CD49f identifies stem-like memory T cells with enhanced therapeutic potency
Proceedings of the National Academy of Sciences · 24.11.2026 · 123 (47)
DOI: 10.1073/pnas.2623940123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 18.11.2026. Verfasst von Katie E Lineburg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Queensland Immunology Research Centre, Infection and Inflammation Program, QIMR Berghofer, Brisbane, QLD 4029, Australia. Hauptthemen laut MEDLINE: Memory T Cells, Integrin alpha6, Immunologic Memory, Immunotherapy, Adoptive. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: William and Hilde Chenhall Research Trust.
Abstract (Originalsprache)
The efficacy of adoptive cell therapies depends on the presence of T cells with durable self-renewal, proliferative capacity, and differentiation potential, yet heterogeneity within starting cell populations remains a major barrier to consistent clinical outcomes. Here, we identify CD49f as a marker of a unique subset of human memory T cells with stem-like characteristics. CD49f Hi memory CD8 + and CD4 + T cells exhibited transcriptional and phenotypic features associated with T cell stemness, including elevated LEF1, TCF1, CCR7, CD27, and CD28, while CD49f Lo cells exhibited effector-like transcriptional programs. Clinical evaluation of solid-organ transplant recipients treated with virus-specific T cells for cytomegalovirus complications demonstrated that autologous T cell therapies manufactured from CD49f Hi -enriched T cells were associated with superior immune reconstitution and greater in vivo expansion of CMV-specific T cells. Functional assays further revealed that CD49f Hi memory T cells possessed enhanced proliferative capacity and transcriptional plasticity following activation. Consistent with these findings, CD19 CAR T cells engineered from CD49f Hi memory T cells demonstrated improved persistence and conferred superior survival in a preclinical lymphoma model. Together, these findings establish CD49f as a marker of a stem-like memory T cell subset with enhanced therapeutic potential and identify CD49f Hi enrichment as a practical strategy to improve the consistency, durability, and clinical efficacy of both virus-specific and CAR T cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queensland Immunology Research Centre, Infection and Inflammation Program, QIMR Berghofer, Brisbane, QLD 4029, Australia.
ORCID-Profile: Katie E Lineburg, Panteha Khaledi, Paulo Martins, Corey Smith
Förderung
- William and Hilde Chenhall Research Trust
Zitieren
APA
Lineburg, K. E., Panikkar, A., Khaledi, P., Leung, C. W., Solomon, M., Martins, P., Le, T., Khanna, R., & Smith, C. (2026). CD49f identifies stem-like memory T cells with enhanced therapeutic potency. Proceedings of the National Academy of Sciences, 123(47). https://doi.org/10.1073/pnas.2623940123
Vancouver
Lineburg KE, Panikkar A, Khaledi P, Leung CW, Solomon M, Martins P, et al. CD49f identifies stem-like memory T cells with enhanced therapeutic potency. Proceedings of the National Academy of Sciences. 2026;123(47). doi:10.1073/pnas.2623940123
BibTeX
@article{Lineburg2026,
author = {Lineburg, Katie E and Panikkar, Archana and Khaledi, Panteha and Leung, Chi Wai and Solomon, Matthew and Martins, Paulo and Le, Thuy and Khanna, Rajiv and Smith, Corey},
title = {CD49f identifies stem-like memory T cells with enhanced therapeutic potency},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {47},
doi = {10.1073/pnas.2623940123}
}
EUVIMED